) HealthCare segment has been performing very well with the
addition of products like Xarelto (anticoagulant), Eylea (eye
drug), Stivarga (oncology), Xofigo (oncology) and Adempas
(pulmonary hypertension) to its portfolio. Bayer has projected
annual peak sales of €7.5 million from these drugs. The new
products are expected to contribute around €2.8 billion to
segmental sales in 2014. The company is also looking to expand
their label beyond current indications.
ALEXION PHARMA (ALXN): Free Stock Analysis
BAYER A G -ADR (BAYRY): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Last week, Bayer initiated the phase IIIb RESPITE (Riociguat
clinical Effects Studied in Patients with Insufficient Treatment
response to PDE-5 inhibitors) study on Adempas (riociguat). The
study is evaluating the clinical effects of Adempas in patients
suffering from pulmonary arterial hypertension (PAH). These
patients demonstrated an insufficient response to treatment with
phosphodiesterase-5 inhibitors (PDE-5i) either as monotherapy or
in combination with an endothelin receptor antagonist (ERA).
The study will evaluate patients who were previously treated with
) Viagra (sildenafil) or
Eli Lilly and Co.
) Cialis (tadalafil) for a minimum of three months.
We note that Adempas is approved in the U.S. for the treatment of
adults suffering from persistent/recurrent chronic thromboembolic
pulmonary hypertension (CTEPH) following surgical treatment or
inoperable CTEPH to improve exercise capacity and WHO functional
class. The drug is also approved in the U.S. for the treatment of
adults suffering from PAH to improve exercise capacity, improve
WHO functional as well as delay clinical worsening.
The drug is approved in Canada for both the above-mentioned
indications and in Switzerland and Japan for CTEPH. Moreover,
Adempas is under review in the EU with a final decision expected
by Jun 30, 2014. In January this year the European Committee for
Medicinal Products for Human Use provided a positive opinion on
the approval of Adempas for both the indications.
We are encouraged by the performance of Bayer's newly launched
pharmaceutical products. Label expansions of these drugs will
boost segmental sales further.
Bayer presently carries a Zacks Rank #4 (Sell). Some
better-ranked stocks include
Alexion Pharmaceuticals, Inc.
) carrying a Zacks Rank #1 (Strong Buy).